SUPERNUS PHARMACEUTICALS, INC. (SUPN) › Weighted Average Diluted SharesSUPERNUS PHARMACEUTICALS, INC. (SUPN) — Weighted Average Diluted SharesAnnual figures by period end, from SEC filings.2010-12-31: 1.59M2011-12-31: 1.61M2012-12-31: 17.44M2013-12-31: 31.85M2014-12-31: 42.26M2015-12-31: 51.16M2016-12-31: 51.71M2017-12-31: 53.30M2018-12-31: 54.10M2019-12-31: 53.82M2020-12-31: 53.69M2021-12-31: 54.36M2022-12-31: 61.68M2023-12-31: 55.51M2024-12-31: 55.96M2025-12-31: 56.45M56.45M2010-12-31Weighted Average Diluted Shares (shares)2025-12-31Period endedWeighted Average Diluted SharesChange YoYSource filing2025-12-3156.45M+0.9%2026-03-02From 2025-01-012024-12-3155.96M+0.8%2026-03-02From 2024-01-012023-12-3155.51M-10.0%2026-03-02From 2023-01-012022-12-3161.68M+13.5%2025-02-25From 2022-01-012021-12-3154.36M+1.2%2023-03-09From 2021-01-012020-12-3153.69M-0.2%2023-03-09From 2020-01-012019-12-3153.82M-0.5%2022-04-13From 2019-01-012018-12-3154.10M+1.5%2021-03-08From 2018-01-012017-12-3153.30M+3.1%2020-02-28From 2017-01-012016-12-3151.71M+1.1%2019-03-01From 2016-01-012015-12-3151.16M+21.1%2018-03-01From 2015-01-012014-12-3142.26M+32.7%2017-03-16From 2014-01-012013-12-3131.85M+82.6%2017-01-20From 2013-01-012012-12-3117.44M+986.4%2015-03-12From 2012-01-012011-12-311.61M+1.1%2013-03-15From 2011-01-012010-12-311.59M—2013-03-15From 2010-01-01Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareEPS (Basic)